Overview
February 21, 2009
San Antonio, TX
Program Directors
Anthony Tolcher, MD
South Texas Accelerated Research Therapeutics (START), San Antonio, TX
Chandra P. Belani, MD
Miriam Beckner Professor of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, PA
February 21, 2009, – Marriott Riverwalk, 889 East Market, San Antonio, TX 78205 – Phone: 210-224-4555
Jointly sponsored by
International Cancer Network and Postgraduate Institute for Medicine
Target Audience
This symposium is directed primarily to medical oncologists, radiation oncologists, surgical oncologists, researchers, pharmacists, and registered nurses interested in new developments for treatment of various malignancies. No specific skill or knowledge other than a basic training in oncology is required for successful participation in this activity. Fellows are also invited to attend.
Statement of Need/Program Overview
This symposium is intended to provide comprehensive updates on biology, diagnosis, screening, and management of cancer. Paradigm shift in the treatment options of cancer will be discussed. This program will facilitate interaction among oncologists and researchers interested in development of novel therapeutics for treatment of cancer. In addition to multimodality therapy, adjuvant therapy and targeted therapies, this symposium will present data on pharmacogenomics and the role of individualized therapy of most promising emerging agents currently in development for the treatment of cancer. The format will include didactic lectures from known thought leaders, question and answer sessions, and ample opportunity for participant interaction with faculty. In-depth discussion of several chemotherapeutic agents at various stages of clinical development for multiple malignancies that target signaling pathways will be given significant focus. Emerging data from ongoing clinical research will be presented.
Learning Objectives
- Describe the integration of novel cytotoxic agents into adjuvant or metastatic treatment regimens for breast cancer, including drugs targeting the HER1, HER2 and VEGF pathways, and methods for optimizing patient selection.
- Identify the impact of combination therapy for previously untreated or treated gastrointestinal and colorectal cancer
- Review novel therapies based on the molecular biology of soft tissue sarcomas.
- Cite recent clinical trial data investigating the use of novel regimens in the treatment of leukemia
- Describe treatment options for prostate cancer
- Review efficacy and toxicity data for multi-targeted kinase inhibitors and other novel agents for the treatment of advance renal cell carcinoma.
- Review current clinical data in the treatment of ovarian and gynecologic malignancies.
- Identify the role of novel agent combinations in the treatment of brain tumors
- Cite recent clinical data regarding the use of agents targeting the EGFR and/or VEGF pathways in the treatment of non-small-cell lung cancer, including potential patient selection and for the development of new drugs
- Review novel genomic targets that are being identified, which can potentially be used for patient selection and for the development of new drugs
- Identify current supportive care issues, in the light of new options of treatment with novel anticancer agents.
Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and International cancer Network. PIM is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
Postgraduate Institute for Medicine designates this educational activity for a maximum of 6.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Pharmacist Continuing Education
Accreditation Statement
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credit Designation
Postgraduate Institute for Medicine designates the morning session of this continuing education activity for 3.5 contact hour(s) (0.35 CEUs) of the Accreditation Council for Pharmacy Education (Universal Program Number - 809-999-09-007-L01-P) and the afternoon session for 3.0 contact hour(s) (0.30 CEUs) (Universal Program Number - 809-999-09-008-L01-P).
Nursing Continuing Education
Purpose
This program will present the latest information on novel therapies for many of the most common cancers encountered by practicing physicians.
Accreditation Statements
CNA/ANCC
This educational activity for 6.5 contact hours is provided by Postgraduate Institute for Medicine (PIM).
PIM is an approved provider of continuing nursing education by the Colorado Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Roberta Granny prior to the live event at 717-531-1078.
Registration Fee
Registration fee partially covers continental breakfast, lunch and syllabus book
□ Physicians $50.00
□ Nurses, Pharmacists, others $30.00
□ Fellows No Registration Fee
□ *Industry $325.00
Payment may be made: □ MC □ Visa □ Discover □ Amex □ Check
Credit Card Number___________________________ Expiration Date_______________
Name as it appears on Credit Card____________________________________________
________________________________________________________________________
________________________________________________________________________
Signature________________________________________________________________
Register online at www.Internationalcancernetwork.com
Please make checks payable to International Cancer Network. Mail checks to P. O. Box 116609, Carrollton, TX 75011-6609
To reserve your place for the meeting, please complete the registration form and fax it 443-267-0016 or 972-492-4082. For questions if any please call 972-939-6206 or E-mail: knaidu@internationalcancernetwork.com
Educational Grants:
This activity is supported by educational grants from:
- Abraxis Oncology
- GlaxoSmithKline
- Novartis Oncology
- Sanofi-Aventis